21.15.gpc3-car t cells
Atypical Teratoid Rhabdoid Tumor
Explore 14 assets in Atypical Teratoid Rhabdoid Tumor →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Baylor College of Medicine
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07513194CT.gov GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atypical Teratoid Rhabdoid Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 21.15.gpc3-car t cells (this asset) | Baylor College of Medicine | P1 | CC · 43 |
| Tazemetostat | Epizyme, Inc. | P2 | B |
| Cyclophosphamide | Medical University of Vienna | P2 | CCC |
| Etoposide | Medical University of Vienna | P2 | CCC |
| Cytarabine | Medical University of Vienna | P2 | CCC |
| Fenofibric Acid | Medical University of Vienna | P2 | CCC |
| Celecoxib | Medical University of Vienna | P2 | CCC |
| Thalidomide | Medical University of Vienna | P2 | CCC |
| Panobinostat | Australian & New Zealand Children's Haematology/Oncology Group | P2 | CCC |
+30 more in the Atypical Teratoid Rhabdoid Tumor cohort
Other indications for 21.15.gpc3-car t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatoblastoma | — | P1 | CC · 43 |
| Wilms Tumor | — | P1 | CC · 43 |
| Rhabdoid Tumor | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 21.15.gpc3-car t cells in Atypical Teratoid Rhabdoid Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2115gpc3-car-t-cells-atypical-teratoid-rhabdoid-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →